Mostrar el registro sencillo del ítem

dc.contributor.authorRamos-Casals, Manuel
dc.contributor.authorDiaz Lagares, Candido
dc.contributor.authorSoto Cardenas, María José 
dc.contributor.authorBrito Zeron, Pilar
dc.contributor.authorCuadrado, Maria Jose
dc.contributor.authorSanna, Giovanni
dc.contributor.authorBertolaccini, Laura
dc.contributor.authorKhamashta, Munther A.
dc.contributor.otherCirugíaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2026-04-08T10:44:07Z
dc.date.available2026-04-08T10:44:07Z
dc.date.issued2011-04
dc.identifier.issn1559-0267
dc.identifier.urihttp://hdl.handle.net/10498/39222
dc.description.abstractThe complexity of the therapeutic approach in lupus nephritis (LN) is increased by the large number of patients who do not respond to first-line therapies and by relapses after initial clinical remission. The emergence of biological agents has increased the therapeutic armamentarium available in these complex situations, but their use is limited by the lack of licensing. We analysed current evidence on the therapeutic use of rituximab in adult LN patients by systematic analysis of seven observational studies published since 2005 (four in 2009), which included 106 LN patients treated with rituximab. A complete or partial therapeutic response was achieved in 73 (69%) patients. The response according to the type of LN was stated in 79 cases: 8 (80%) patients with type III LN had a favourable, 26 (67%) of those with type IV, 4 (57%) of those with type V and 18 (78%) of those with mixed membranous-proliferative LN. The main factors associated with no response were younger age, black race and lack of CD19(+) cell depletion. The lowest rates of complete response were observed in patients with type V LN, especially those with associated proliferative lesions. Although it is not yet possible to make definite recommendations, the global analysis of these cases supports the off-label use of rituximab in severe, refractory LN cases.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.sourceClinical Reviews in Allergy and Immunology - 2011, vol. 40, nº 3, pp. 159 - 169es_ES
dc.subjectBiological therapieses_ES
dc.subjectLupus nephritises_ES
dc.subjectRituximabes_ES
dc.titleRituximab Therapy in Lupus Nephritis: Current Clinical Evidencees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsclosed accesses_ES
dc.identifier.doi10.1007/s12016-010-8205-3
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem